ストックスクリーナーアプリを入手
1.63
2.40%
-0.04
Adc Therapeutics Sa (ADCT) 最新ニュース
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR
Is Adc Therapeutics SA (ADCT) a good investment opportunity? - US Post News
Investing in Adc Therapeutics SA (ADCT) Is Getting More Attractive - Knox Daily
Several ADC Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Adc Therapeutics SA (ADCT) Shares Down Despite Recent Market Volatility - The News Heater
Adc Therapeutics SA (ADCT) stock analysis: A comprehensive overview - US Post News
Upward Trajectory: Adc Therapeutics SA (ADCT) Posts a Slidee, Closing at 1.58 - The Dwinnex
The Attractiveness of Investing In Adc Therapeutics SA (ADCT) is Growing - Knox Daily
BlackRock, Inc.'s Strategic Acquisition of ADC Therapeutics SA Shares - GuruFocus.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Strategic Stock Options Grant: ADC Therapeutics Secures Top Talent with 26.8K Share Package - StockTitan
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - BioSpace
ADC Therapeutics Takes Center Stage: Key Investor Presentation Coming at Major Biotech Conference - StockTitan
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
Brokers Set Expectations for ADCT FY2025 Earnings - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Achieves Profitability with ZYNLONTA - TipRanks
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
ADCT Stock Hits 52-Week Low at $1.71 Amid Market Challenges - Investing.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push | ADCT Stock News - StockTitan
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate - StockTitan
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Guggenheim Reaffirms “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Adc therapeutics sees $609,000 in stock purchases by Redmile - Investing.com South Africa
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):